Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer

  • Dr. Gericke brings extensive experience in the research and development of radioligand therapies
  • Appointment coincides with launch of Ariceum International AG in Basel, Switzerland

Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Germo Gericke, M.D., as Chief Medical Officer.

Germo joins Ariceum from Novartis, where he has recently served as Chief Medical Officer and Global Head of Research and Development at Advanced Accelerator Applications (AAA), a Novartis company specializing in the field of nuclear medicine. Germo will be based at Ariceum’s newly opened subsidiary in Basel, Switzerland. Basel offers one of the largest talent pools in Europe for the development and commercialization of innovative pharmaceuticals.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “I am delighted to welcome Germo to the Ariceum leadership team at a pivotal time of Company growth and clinical development. Germo brings with him a wealth of experience in the field of radiopharmaceutical therapy and it is a testament to the potential of Ariceum’s theranostic portfolio that someone of Germo’s calibre has chosen to join our team. Germo will build and lead the clinical development and operations team out of our new subsidiary in Basel.”

Germo Gericke, M.D., Chief Medical Officer of Ariceum Therapeutics, commented: “I am excited to join Ariceum with its focus on systemic targeted radiotherapy. Ariceum is actively working to develop innovative medicines for the diagnosis, monitoring, and precision treatment of certain aggressive neuroendocrine cancers, such as small cell lung cancer (SCLC). These cancers have few treatment options and poor prognoses, and so I look forward to contributing to Ariceum’s mission to improve the lives of those facing these very challenging diseases.”

Germo joins Ariceum from Advanced Accelerator Applications (AAA), a Novartis company developing targeted radioligand therapies and precision imaging radioligands for oncology indications. As a member of the Executive Leadership Team, he held positions of Chief Medical Officer and Head of Research and Development building a global R&D organization for Radioligand Therapies. Prior to AAA, Germo served as Franchise Global Program Head in Oncology Development and in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas, having joined Novartis in 2001 from McKinsey & Company. Germo studied medicine at Charité University Hospital in Berlin and holds an MD from the University of Heidelberg.

ENDS

For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Hollie Vile, Charlotte Hepburne-Scott, Zoe Bolt, Elena Bates
Tel: +44 (0) 20 3882 9621
Email: ariceum@optimumcomms.com

Notes to Editors

About Ariceum Therapeutics
Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs), some aggressive cancers such as small cell lung cancer (SCLC) and the childhood cancer, neuroblastoma, all of which have few treatment options and poor prognoses. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours.

Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ariceum is headquartered in Berlin, with operations in Germany and Switzerland and activities currently across Europe, North America and Australia.

Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap and Pureos Bioventures. For further information, please visit www.ariceum-therapeutics.com

Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership

  •  AmbioPharm to provide cGMP peptide synthesis and support for clinical radiopharmaceutical manufacturing

BERLIN, Germany and NORTH AUGUSTA, S.C., USA, 27th October  2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing  radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, and AmbioPharm, a global peptide contract development and manufacturing organization, today announce that they have entered into a strategic partnership for the manufacture and supply of peptide conjugates to be used by Ariceum in future clinical studies.

AmbioPharm is supporting Ariceum with cGMP manufacturing and supply of peptide conjugates that will be radio-labelled as the radiopharmaceutical end-product used in upcoming clinical trials.  Radio-labelled receptor-binding peptides are an important class of radiopharmaceuticals for targeted tumor diagnosis and therapy and will be used in clinical trials of Ariceum’s lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers, currently in Phase I/II. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours.

As a peptide contract development and manufacturing organization (CDMO) providing cGMP peptide APIs with capabilities ranging from research to commercial scales, AmbioPharm actively engages with innovative biopharmaceutical companies in developing first-in-class, best-in-class, and breakthrough peptide technologies that utilize AmbioPharm’s peptide manufacturing expertise and in-depth scientific experience in novel and conventional peptide chemistry.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “Ariceum is very pleased to be partnering with AmbioPharm.  As we build our platform and continue to advance our lead product, satoreotide, towards clinical trials, we are delighted to be supported by such a well-established and reliable manufacturer of high-quality, FDA-inspected peptide APIs.”

Michael W. Pennington, PhD, Chief Scientific Officer at AmbioPharm, added: “We are delighted to play a role in the synthesis of this peptide ‘theranostic’ that will be a valuable resource for the treatment and diagnosis of certain hard-to-treat neuroendocrine cancers.”

For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Hollie Vile, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: ariceum@optimumcomms.com

AmbioPharm, Inc.
Mark DaFonseca, EVP Sales & Global Business Development
Email: mark.dafonseca@ambiopharm.com

Ariceum Therapeutics Announces Planned Retirement of CMO

BERLIN, 14 October 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces that Chief Medical Officer, Alexander “Sandy” McEwan, M.D., will retire from the Company as Chief Medical Officer on the 15th of October 2022. Germo Gericke, M.D., former Chief Medical Officer of Advanced Accelerator Applications (AAA), a Novartis company, will join the Company on a consultancy basis as part of a planned transition. Sandy will work closely with Germo and the leadership team to ensure a smooth transition and will remain available in a part-time advisory role.

Eduardo Bravo, Chairman of Ariceum Therapeutics, said: “On behalf of the Board, I would like to thank Sandy for his experience and leadership in helping to build Ariceum from start up through to launch, and for his significant contributions in the development of our clinical lead asset, satoreotide, which will be used as a ‘theranostic’ for both the diagnosis and treatment of tumours expressing the SST2 receptor. We wish him all the best for his pending retirement. We are delighted to welcome Germo who will work closely with the leadership team in the coming months on a consultancy basis as we continue to build and progress our technology platform and advance satoreotide.”

Sandy McEwan, M.D., Chief Medical Officer of Ariceum Therapeutics, commented: “I am very proud of all we have achieved in the past year. I would like to thank all my colleagues in the Ariceum team for all their contributions and for the progress we have made in a short time. I wish them well in their ongoing efforts to discover and develop innovative new radiopharmaceutical treatments for patients suffering from hard-to-treat cancers, and for their families.”

ENDS

For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Mary Clark, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: ariceum@optimumcomms.com

Notes to Editors

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of the somatostatin type 2 receptor (SST2) which is overexpressed in neuroendocrine tumours (NETs), some aggressive cancers such as small cell lung cancer (SCLC) and the childhood cancer, neuroblastoma, all of which have few treatment options and poor prognoses. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours.

Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ariceum is headquartered in Berlin, with operations in Germany and activities currently across Europe, North America and Australia.

Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap and Pureos Bioventures. For further information, please visit www.ariceum-therapeutics.com

 Ariceum Therapeutics Q4 2022 Investor and Scientific Conference Attendance 

BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces that its senior management team will be attending and hosting meetings at the following investor and scientific conferences in the fourth quarter of 2022 

Terachem 2022: The Fourth International Symposium on Technetium and Other Radiometals in Chemistry and Medicine 
14-17 September 2022, Forum Brixen, Bressanone, Italy 

9th Immunotherapy of Cancer Conference (ITOC) 
22-24 September 2022, Klinikum der Universität München, Munich, Germany 

Optimum 14th Annual Healthcare Investor Conference 
6 October 2022, Wellcome Collection, London, UK 

European Association of Nuclear Medicine (EANM) 35th Annual Congress 
15-19 October 2022, Barcelona International Convention Centre, Barcelona, Spain 

BIO-Europe 2022 
24-26 October 2022, Leipzig Messe, Leipzig, Germany 

4th Targeted Radiopharmaceuticals EU Summit Europe 
6-8 December 2022, Leonard Royal, Amsterdam, Netherlands 

Presentation by: Chief Executive Officer, Manfred Rüdiger, Ariceum Therapeutics
Title: New Life for Satoreotide-The Antagonist Moves
Date & Time: 6 December, 12.00pm CET

European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress 
7-9 December 2022, Palexpo exhibition centre, Geneva, Switzerland 

If you would like to meet with the Ariceum Therapeutics team at any of the above events, please see contact details below. 

For further information, please contact: 

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Hollie Vile, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: ariceum@optimumcomms.com

 

Ariceum Therapeutics Appoints Chief Business Officer

BERLIN, 7 July 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer. Appointed from 1 July 2022, Serge will oversee all business development aspects of the company, leveraging his considerable expertise in licensing and transactions over a 20-year career in business development within the Life Sciences sector. He will work closely with the Ariceum leadership team to establish long-term strategic and value-creating collaborations with industry leaders as well as renowned academic groups in the field of radiopharmaceuticals.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “We are delighted to have attracted such a high calibre individual for this important role. Serge has direct experience in the licensing of radiopharmaceutical therapies and is very well connected in our industry bringing an international approach to the development of our business. We look forward to working together as we continue to build our pipeline for the development of novel drugs for systemic targeted radiation therapy.”

Serge Sagodira, new Chief Business Officer of Ariceum Therapeutics, added: “I am excited to be taking on this new role, working with a team of experienced industry professionals to advance products that I believe have the potential to transform the treatment of very challenging cancers and ultimately significantly improve patient outcomes. I have been following the progress of Ariceum’s lead asset with interest over recent years and I am privileged to have been given the opportunity to join the team.”

Serge joins Ariceum from Swiss pharmaceutical company, Debiopharm International SA, where he worked for almost 10 years across a number of licensing and transaction roles culminating in Director, Licensing Transactions. Under Serge’s leadership in this position, Debiopharm, which develops therapeutics and biologics in the field of oncology and antimicrobial resistance, completed licensing agreements with Merck KGaA and Takeda. Serge has also completed several in-licensing transactions of early-stage programs. In addition, Serge also spent two years as Director of Business Development at DNDi, a not-for-profit R&D organization dedicated to neglected diseases supervising the structuring of complex collaborations. Serge has a PhD in Life Sciences from the University of Tours in France.

ENDS

For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Mary Clark, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: ariceum@optimumcomms.com

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

  • Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures
  • Developing novel drugs for systemic targeted radiation therapy (STRT)
  • Proceeds will be used to advance lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers
  • Led by industry veteran Manfred Rüdiger as CEO, and world-renowned expert in oncology and nuclear medicine, Sandy McEwan as CMO

BERLIN, 8 June 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces the successful completion of an oversubscribed EUR 25 million Series A financing round. Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap who also co-led the financing that was joined by Pureos Bioventures. Ipsen transferred assets, and all corresponding rights into the Company in late 2021.

The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, satoreotide. Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in many cancers, including certain hard-to-treat cancers such as small cell lung cancer (SCLC), high-grade neuroendocrine tumours (NETs) and neuroblastoma, an aggressive, rare type of cancer that occurs mainly in young children. Satoreotide will be used as a ‘theranostic’ for both the diagnosis and treatment of tumours expressing the SST2 receptor. Satoreotide is in early clinical development and, as of today, has been administered to more than 100 patients including more than 150 therapeutic administrations.

Ariceum is led by a highly experienced management team with a strong track record and expertise in clinical trials, systemic targeted radiation therapy and radiopharmaceutical development, as well as launching and commercialising diagnostic and therapeutic products in a variety of indications worldwide.

In conjunction with the financing, Karin Kleinhans of EQT Life Sciences, Per Samuelsson of HealthCap and Martin Münchbach of Pureos Bioventures will join Ariceum’s board of directors together with Eduardo Bravo, CEO of EBAC, who has been elected as chairman of the board.

Founded in 2021, Ariceum is headquartered in Berlin, with operations in Germany and activities currently across Europe, North America and Australia.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “We are very pleased to attract this outstanding syndicate of venture capital and corporate investors which validates our approach to developing our lead radiopharmaceutical product, satoreotide. I am excited to lead an exceptional team as we continue to build our platform and advance satoreotide for systemic targeted radiation therapy (STRT) to visualize and treat neuroendocrine tumors and certain other more aggressive cancers.”

Karin Kleinhans, PhD, Partner at EQT Life Sciences, stated: “We founded Ariceum with the aim to build a European leader in targeted radiopharmaceuticals.  We are delighted to support the Company in the development of its innovative technology to create more effective treatments for patients suffering from hard-to-treat cancers which are currently not adequately addressed by existing therapies, in addition to neuroendocrine cancers expressing the receptor.”

Per Samuelsson, Partner at HealthCap, stated: “We are proud to have been involved with the Company since its early days and are very impressed with the progress achieved to date. We believe Ariceum’s innovative theranostic approach to diagnose and treat different types of cancers is world-leading and we look forward to supporting the Company through the next stages of growth.”

Martin Münchbach, PhD, Managing Partner at Pureos Bioventures, added: “We are honoured to join this round with HealthCap and EQT Life Sciences and believe it will be a tremendous joint effort to bring Ariceum to the next level. Ariceum understands the power of radiopharmaceuticals which will enable the Company to develop better targeted drugs to eradicate cancer more effectively with less side-effects.”

ENDS

For further information, please contact:

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Supriya Mathur, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3922 1906
Email: ariceum@optimumcomms.com